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ORIGINAL RESEARCH
A Color Flow Tract in
Ultrasound-Guided Random Renal
Core Biopsy Predicts Complications
Marie-Helene Gagnon, MD, Michael F. Lin, MD, Samantha Lancia, MS, Amber Salter, PhD,
Motoyo Yano, MD, PhD
Objectives—To determine patient and procedural risk factors for major compli-
cations in ultrasound (US)-guided random renal core biopsy.
Methods—Random renal biopsies performed by radiologists in the US depart-
ment at a single institution between 2014 and 2018 were retrospectively reviewed.
The patient’s age, sex, race, and estimated glomerular filtration rate (eGFR) were
recorded. The biopsy approach, needle gauge, length of cores, number of throws,
and presence of a color flow tract were recorded. Outcome data included minor
and major complications. Associations between variables were tested with χ2 ana-
lyses and univariable/multivariable logistic regression models.
Results—A total of 231 biopsies (167 native and 64 allografts) were reviewed. There
was no significant difference in the sex, age, race, or eGFR between native and allo-
graft groups. The overall rate for any complication was 18.2%, with a 4.3% rate of
major complications, which was significantly greater in native compared to allograft
biopsies (6% versus 0%; P = .045). A risk analysis in native biopsies only showed that
major complications were significantly associated with a low eGFR such that
patients with stage 4 or 5 kidney disease had higher odds of complications (odds
ratio [95% confidence interval]: stage 4, 9.405 [1.995–44.338]; P = .0393; stage
5, 10.749 [2.218–52.080]; P = .0203) than patients with normal function (eGFR
>60 mL/min). The presence of a color flow tract portended a 10.7 times greater risk
of having any complication (95% confidence interval, 4.595–24.994; P < .001).
Other procedural factors were not significantly associated with complications.
Conclusions—There is an increased risk of major complications in US-guided
random native kidney biopsy in patients with a low eGFR (<30 mL/min) and a
patent color flow tract in the immediate postbiopsy setting.
Key Words—complication; Doppler; renal biopsy; ultrasound guided
S ince the first renal biopsy was performed in the 1950s,percutaneous renal biopsies have become an important tool inthe diagnosis and management of renal disease. These biopsies
allow for histologic diagnosis of renal disease not obtainable by any
other means.1,2 The introduction of the spring-loaded core biopsy
needle in the 1980s led to an increase in the safety and yield of renal
biopsy,1 but bleeding remains a substantial complication.3–6Bleeding
is considered a minor complication when a small hematoma requires
no or nominal therapy but is considered a major complication when
the patient requires hospitalization, transfusion, vascular emboliza-
tion,ornephrectomy tocontrol thebleedingor if thebleeding leads to
permanent damage or death.7
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There are several established risk factors for
bleeding complications in the setting of renal biopsy.
Absolute contraindications to percutaneous renal
biopsy include uncontrolled severe hypertension,
inability to cooperate with the biopsy, and uncontrol-
lable bleeding diathesis. Relative contraindications
may include severe azotemia, renal anatomic abnor-
malities, anticoagulation, pregnancy, and urinary tract
infections.4,8 There are scattered reports of female
sex,6 obesity,6,8 and laboratory factors such as anemia
and thrombocytopenia6,9,10 as risk factors for compli-
cations. However, hypertension5,11,12 and renal fail-
ure3,6,9,11,13,14 are more consistently reported risk
factors for complications. Technical factors related to
biopsy may also affect the complication risk. A recent
meta-analysis showed that larger-gauge needles
(14 gauge) were associated with more transfusion
events compared to 16- and 18-gauge needles.3 Other
technical factors, such as the axis of biopsy, length of
throw, and number of passes, have not been studied
extensively. Although patent tracts have been shown
to occur with renal biopsies,15 to our knowledge, the
prognostic importance of a patent color flow tract
after renal biopsy has not been investigated.
Materials and Methods
This study and its reporting were performed as a
quality improvement project and was deemed “not
human subject research” by the Institutional Review
Board (ID number 201904188), and the requirement
for informed consent was therefore waived.
Study Population
Patients were identified from a database of all patients
who underwent ultrasound (US)-guided random
renal core biopsies by the radiology department at
our institution between November 2014 and August
2018. If a single patient received more than a single
biopsy during that time frame, data from each biopsy
event was collected and considered independently.
Demographic Data Points
For each biopsy, the patient’s age at the time of
biopsy, sex, race, and status as inpatient or outpa-
tient were collected. The patient’s serum creatinine
level at the time of biopsy was recorded to calculate
an estimated glomerular filtration rate (eGFR) using
the Modification of Diet in Renal Disease equation
as follows: eGFR = 175 × (serum creatinine) –
1.154 × (age) – 0.203 × 0.742 (if female) × 1.212
(if African American). The patient’s height and
weight were used to unadjust the calculation for the
ideal body surface area.16
Biopsy Data
Real-time US-guided biopsies were performed with a
16- or 18-gauge spring-loaded core biopsy needle
(BioPince; Argon Medical Devices, Inc, Frisco, TX)
under local anesthesia only with onsite evaluation of
specimens by a cytotechnologist to assess specimen
adequacy. Generally, at least 2 cores were favored,
but ultimately, the radiologist performing the biopsy
determined the total number of cores obtained on
the basis of the specimens obtained and the patient’s
status.
An immediate postbiopsy US examination was
performed to evaluate for hemorrhage or hematoma
and to assess for the presence or absence of a color
flow tract. Postbiopsy images were obtained for all
cases. During the time frame for these biopsies,
regardless of the site of biopsy, the departmental
practice was to return inpatients to their hospital
units for observation. Outpatients were observed for
2 hours after biopsy, at which time outpatients were
discharged if asymptomatic and vital signs were sta-
ble. The radiology report was used to determine the
location of the biopsied kidney (right or left native or
allograft), needle gauge, number of throws, and throw
length. To determine the approach for biopsy (trans-
verse versus longitudinal relative to the axis of the
kidney), the images from the biopsy were reviewed
by a fellowship-trained abdominal radiologist with
greater than 10 years of experience. If the approach
was ambiguous based on the images, it was recorded
as indeterminate. The presence of a patent color flow
tract (Figure 1) documented either in the radiology
report or on the immediate postbiopsy images was
also recorded and categorized as indeterminate if
there was no statement regarding a color flow tract in
the report or not documented on the images. The
report was reviewed for the use of Gelfoam (Pfizer,
New York, NY) or thrombin injection into the biopsy
tract. Cases were excluded if the approach to biopsy
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or the presence of a color flow tract was indetermi-
nate or if a hemostatic agent was used (Figure 2).
The electronic medical record was interrogated
for descriptions of complications in radiology reports
and progress notes, any subsequent imaging examina-
tions, drops in the hemoglobin level, the need for
transfusion, or the need for additional procedures.
For outpatients, the medical record was reviewed to
determine whether the patient returned to the
emergency department or required admission in the
48 hours after the biopsy.
Major and minor complications were classified
according to the Society of Interventional Radiology
Standards of Practice Committee.7 Briefly, for the
purposes of this study, minor complications consisted
of nominal therapy and overnight admission for
observation only; examples included a perinephric
hematoma requiring only observation. Major compli-
cations consisted of bleeding requiring therapy with
hospitalization, such as transfusion or intervention
such as vascular embolization, permanent adverse
sequelae, or death.
Statistical Analyses
Categorical variables were summarized as frequencies
(percentages). Continuous variables were summa-
rized as medians (interquartile ranges). Differences
for each of the measures between groups were deter-
mined by the χ2 or Fisher exact test as appropriate
for categorical data or the Kruskall-Wallis test for con-
tinuous measures. Univariate logistic regression
models were used to determine predictors of any,
minor, and major complications in the native kidney
biopsy population only. Stepwise multivariate logistic
regression with the Bayesian information criterion for
selection was used to determine factors associated
Figure 1. Example of a color flow tract after core biopsy of the
kidney.
Figure 2. Schema for the study population.
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with postbiopsy complications. All tests were 2 sided,
and a significance level of .05 was used. SAS version
9.4 software (SAS Institute Inc, Cary, NC) was used
to conduct data analyses.
Results
Patient Population
The US biopsy database for random renal biopsies
included 251 cases in the almost 4-year time frame of
this study, with 185 biopsies of the native kidney and
66 of an allograft. In the native kidney group,
4 patients underwent 2 separate biopsy events during
the study period. In the allograft group, 2 patients
underwent 2 biopsy events, and 1 patient underwent
3 biopsy events. There were 18 exclusions in the
native kidney group and 2 exclusions in the allograft
group (Figure 2). There were no significant differ-
ences in the sex, race, or age between the groups. The
admission status was significantly different between
the groups, as patients with allograft biopsies were
overwhelmingly of the inpatient rather than outpa-
tient status (P < .001; Table 1). There was no signifi-
cant difference in the eGFR between the groups.
Native Compared to Allograft Biopsy
Overall, the rate of developing any complication after
kidney biopsy was 18.2%, and the rate of developing
a major complication was 4.3%. Major complications
were significantly associated with native rather than
Table 1. Demographic Data for the Native Kidney and Allograft






(n = 64) P
Sex .36
Female 80 (48) 35 (55)
Male 87 (52) 29 (45)
Race .62
African American 66 (40) 23 (36)
Non–African American 101 (60) 41 (64)
Age, y .76
Median 54 53
Interquartile range 38–64 41–64
Range 18–88 21–80
Admission status <.001
Inpatient 70 (42) 59 (92)






Data are presented as number (percent) and median (interquartile
range) where applicable.
Table 2. Comparison of Biopsy Data Points for Native Kidney Versus Allograft
Factor Native (n = 167) Allograft (n = 64) Total (n = 231) P
Any complication .077
No 132 (79.0) 57 (89.1) 189 (81.8)
Yes 35 (21.0) 7 (10.9) 42 (18.2)
Minor complication .43
No 142 (85.0) 57 (89.1) 191 (86.0)
Yes 25 (15.0) 7 (10.9) 31 (14.0)
Major complication .045
No 157 (94.0) 64 (100.0) 212 (95.5)
Yes 10 (6.0) 0 (0.0) 10 (4.5)
Needle gauge .19
16 16 (9.6) 10 (15.6) 23 (10.4)
18 151 (90.4) 54 (84.4) 199 (89.6)
Length of throw, cm 2.0 (2.0–3.0) 2.0 (2.0–3.0) 2.0 (2.0–3.0) .49
Number of throws 2.0 (1.00–2.0) 2.0 (1.0–2.0) 2.0 (1.00–2.0) .98
Biopsy approach .94
Longitudinal 87 (52.1) 33 (51.6) 115 (51.8)
Transverse 80 (47.9) 31 (48.4) 107 (48.2)
Presence of color flow tract .013
No 127 (76.0) 58 (90.6) 176 (79.3)
Yes 40 (24.0) 6 (9.4) 46 (20.7)
Number of glomeruli 25 (16.0–34.0) 23.0 (18.0–33.0) 25.0 (17.0–33.0) .75
Data are presented as number (percent) and median (interquartile range) where applicable.
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allograft biopsies; no major complications occurred
with allograft biopsies (Table 2). There was no signif-
icant difference in technical factors between the
native and allograft biopsies with respect to the nee-
dle gauge, length of throw, number of throws, or
biopsy approach (Table 2). Color flow tracts were
present in a significantly greater proportion of native
kidneys than allografts (P = .013; Table 2).
Native Kidney Biopsy Risk Factors
To further interrogate the risk factors for complica-
tions in renal biopsies, the native kidney cohort was
evaluated separately, as major complications only
occurred in this group (Table 3). The risk of any
complication increased by 0.02% for each 1-unit
decrease in the unadjusted eGFR. Compared to renal
biopsies in patients with stage 1 or 2 chronic kidney
disease (eGFR >60 mL/min), patients with stage
4 and 5 kidney disease (eGFR <30 mL/min) had
9.405 (95% confidence interval, 1.995–44.338;
P = .0393) and 10.749 (95% confidence interval,
2.218–52.080; P = .0203) increased odds of complica-
tions, respectively. Independent of eGFR, patients
with a color flow tract were 10.7 times more likely to
have any complication (95% confidence interval,
4.595–24.994; P < .001) than patients without a
color flow tract. In the stepwise multivariate logistic
regression analysis, only a color flow tract was pre-
dictive of any complication (P < .0001). A probabil-
ity plot for complications plotted against the eGFR
for patients with and without a color flow tract in
shown in Figure 3. The positive predictive value of
the color flow tract for any complication was 55%,
and the negative predictive value was approxi-
mately 90%.
When multiple variables (needle gauge, length of
throw, number of throws, >3 throws, biopsy approach,
color flow tract, eGFR, and number of glomeruli) were
entered separately into a predictive model, only the
presence of a color flow tract (P < .0001) and eGFR
(P = .0034) were predictive of any (minor or major)
complication. When these variables were entered into
a predictive model for major complications only, the
presence of a color flow tract approached but does not
reach significance (P = .0588), and the eGFR was not
significantly predictive (P = .1959).
Table 3. Patients With Native Kidney Biopsy Who Had Major Complications
Patient Age, y Sex
eGFR
(Unadjusted),
mL/min Description of Complication Admission Status
Management of
Complication
1 64 Male 11.7 Large perinephric hematoma with
dropping hemoglobin
Inpatient Catheter angiography with
renal artery embolization
2 64 Male 18.8 Hematuria with dropping
hemoglobin
Inpatient Blood transfusion
3 67 Male 18.3 Large perinephric hematoma, AVF Inpatient Blood transfusion
4 42 Female 20.4 Large perinephric hematoma with
dropping hemoglobin
Inpatient Catheter angiography but
no intervention
5 62 Male 24.1 Large perinephric hematoma with
pseudoaneurysm
Outpatient, admitted Observation
6 56 Male 24.6 Small perinephric hematoma and
AVF, hematuria followed by
inability to void bladder
Outpatient, admitted Observation, patient
declined catheter
angiography
7 66 Female 9.7 Large perinephric hematoma with
pseudoaneurysm and AVF
Outpatient, admitted Blood transfusion
8 55 Male 155.8 No perinephric hematoma but





complication 4 d after
biopsy, admitted for
observation
9 40 Male 7.8 Large perinephric hematoma with
dropping hemoglobin
Inpatient Catheter angiography with
renal artery embolization,
transfusion
10 18 Female 12.9 Perinephric hematoma with patent
color flow tract, hematuria
Inpatient Blood transfusion
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Discussion
The overall complication rate inclusive of minor and
major complications was 18.2%, similar to the litera-
ture.17,18 The overall major complication rate in all
kidneys was 4.3% but 6% in native kidneys; no major
complications occurred in allograft biopsies. The
greater complication rate in native kidneys compared
to allografts is consistent with the literature.13,19,20
Our complication rates were within the range of
0% to 7.4% major complication rates reported in a
2012 meta-analysis of 34 studies by Corapi et al.3 Our
rates were also within the range of more recent
studies.6,21–24 Simard-Meilleur et al21 published a ret-
rospective single-institution study of 312 biopsies
and showed a transfusion rate of 9%, with vascular
embolization required in 1% of patients. A recent
single-institution retrospective study showed a major
complication rate of 1.64% in a cohort of more than
2200 patients.6 Our complication rate was reflective
of several factors, including the patient population.
During the period of our study, 1 of 4 hospital service
areas performed random renal biopsies at our institu-
tion: nephrology, US, computed tomography, and
interventional radiology. Biopsies performed by the
US service were generally referred by nephrology
because of availability, a failed prior attempt at biopsy,
a large patient body habitus, or otherwise higher risk.
This practice may have resulted in the skewing of our
population to those biopsies that were technically chal-
lenging. The phenomenon of referring patients with a
larger body habitus from nephrology to radiology is a
known practice.24 There were also other technical fac-
tors that may have affected the comparison of compli-
cation rates between our institution and others; for
example, we primarily used the BioPince biopsy needle
compared to the Monopty needle (Bard, Murray
Hill, NJ) used by Monahan et al.6
Given the presence of major complications in only
the native kidney biopsy population, our analysis of
complications was performed in only the native kidney
population. We found that procedural factors such as
the needle gauge, length of throw, number of throws,
and biopsy approach did not affect the complication
rate. Ninety percent of our biopsies were performed
with an 18-gauge needle. This number contrasts with
approximately 80% of biopsies performed with a
16-gauge needle in the study by Simard-Meilleur et al,21
which resulted in an approximately 10% major compli-
cation rate, and a combination of 14- and 16-gauge
needles by Whittier et al,13 which resulted in a 6.5%
complication rate. Although Monahan et al6 found that
more than 4 throws were associated with complications,
we did not find an association with the number of
throws, similar to other studies.12,13,23,25 We also found
that the biopsy approach (transverse or longitudinal)
did not affect the complication rate. Of the few studies
that have examined the effects of technical factors on
the complication risk,26–28 none specifically compared
the biopsy approach, although Li et al29 found complica-
tions only with the sagittal approach.
Although we did not examine laboratory factors
linked to the complication risk,3,5 biopsies are gen-
erally not performed by the US department unless
minimum standards for laboratory values (platelet
count >50,000/mm3, international normalized ratio
<1.5, and partial thromboplastin time of 25–37
seconds) are satisfied and antiplatelet and anticoag-
ulant medications are held for the appropriate
period around the time of biopsy. Other patient
factors such as female sex,30 obesity,6,8 and hyper-
tension,3,19,23,25,30 which have previously been
linked to greater patient risk, were also not exam-
ined. Although we did not examine the acuity of
renal failure, which has been shown to be a risk fac-
tor for biopsy complications,23,25,30 we did assess
the severity of renal failure by the eGFR. A low
eGFR was predictive of postbiopsy complications,
especially in patients with stage 4 or 5 chronic
Figure 3. Probability plot for complications (minor or major) after
core biopsy of the native kidney.
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kidney disease (unadjusted eGFR <30 mL/min).
This finding was consistent with the increasing vol-
ume of literature linking poorer renal function with
complications, 3,6,11,19,23,24,28,30,31 especially an
eGFR lower than 30 mL/min.6,23
We found that the presence of a color flow tract
was a significant predictor of complications, such that
patients with this finding were 10.7 times more likely
to have a minor or major complication. Although prior
studies investigated the prognostic significance of this
tract in the liver,32 especially its persistence after
5 minutes of manual compression, we are unaware of
prior studies showing the significance of this finding in
renal biopsies. In 2007, Werner et al15 investigated
color flow abnormalities in the kidney immediately
after biopsy with the primary aim of determining the
natural history of presumed postbiopsy arteriovenous
fistulas (AVFs). In their cohort of 77 patients studied
prospectively, 7 patients were found to have color flow
abnormalities that did not meet criteria for an AVF.
These color flow tracts were identified at the site of
biopsy and presumably corresponded to postbiopsy
bleeding, which resolved spontaneously for all
7 patients. In 2011, McGahan et al33 showed an associ-
ation between a color tract after lesion ablation and
development of postprocedural hematoma, but there
was no association with a major complication requiring
intervention. These results, however, are difficult to
interpret, as the tract was coagulated before electrode
removal. Our results show that the presence of a color
flow tract is associated with complications after
biopsy. Due to the retrospective nature of this study,
it was not possible to ascertain whether the color flow
tract appeared with the first pass or whether it devel-
oped with subsequent passes. However, the presence
of this color flow tract after the first pass may help
inform the risk of additional passes, should they be
required because of insufficient glomeruli. A larger
prospective study would be necessary to evaluate the
true prognostic nature of a color flow tract after renal
biopsy.
There were several limitations to this study, most
notably its retrospective design and the inherent limita-
tion in discovering data points not clearly documented
by images or in the report. Although we excluded such
patients when there was ambiguity regarding the biopsy
technique, a prospective design would have allowed
for more confidence in biopsy data points. We also
excluded cases (n = 5) in which the presence or absence
of a color flow tract could not be ascertained from the
images or the report. However, it is possible that some
cases that were ultimately categorized as “no color flow
tract” did have a color flow tract transiently. The radiol-
ogist may have held pressure after seeing a color flow
tract and only saved an image after the color flow tract
had resolved. It may therefore be more appropriate to
consider our conclusions regarding the color flow tract
for those tracts that are persistent after some reasonable
time of holding pressure at the site of sampling. A pro-
spective evaluation of the timing of this color flow tract
may be helpful to further stratify patient risk, as has been
shown in the liver.32 Second, we excluded patients in
whom a hemostatic agent was injected into the biopsy
tract, as that would likely alter the natural history of any
bleeding, potentially altering the classification of a com-
plication frommajor to minor or minor to none. Includ-
ing these patients who received hemostatic agents may
have increased the overall complication rate, although
that may have also been offset by those radiologists who
chose to prophylactically inject hemostatic agents into
the biopsy tract on completion of the biopsy. Third, we
did not interrogate pathology and clinical reports to
determine whether the core samples were adequate to
answer the clinical question.
In conclusion, the presence of a color flow tract
at random native kidney biopsy in patients with poor
renal function as manifested by a low eGFR, espe-
cially less than 25 mL/min, should be surveilled
closely, as this finding is associated with an increased
risk of major complications.
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